The deal, worth up to $2.6 billion, gives Novo an early-stage oral GLP-1/GIP drug designed to be taken once a week — a bid to leapfrog today’s daily pills as its rivalry with Lilly intensifies.
Both remove amyloid from the brain and modestly slow early Alzheimer’s. They differ in how they are given, how long treatment lasts, the risk of brain swelling, and cost — differences that matter when choosing.
The drugmaker is buying a stake in the developer of the bispecific antibody that beat Keytruda in a lung cancer trial, and will test it alongside its antibody-drug conjugates in gastrointestinal cancers.
TrumpRx.gov lists discounted cash prices for brand-name drugs, including GLP-1s such as Zepbound, Wegovy and Ozempic. Here is how it works, what the prices are, and when it is — and isn’t — the cheapest option.
Children with idiopathic nephrotic syndrome have relied on steroids since the 1950s. Roche’s obinutuzumab is now approved to keep frequently relapsing patients in remission — offering a way off repeated steroid courses.
Tavapadon targets a narrower set of dopamine receptors than older drugs, aiming to ease movement symptoms with fewer of the side effects that make dopamine agonists hard to tolerate.
Lilly’s triple-hormone drug produced some of the largest weight loss ever seen in obesity trials. It isn’t approved yet — and a fast-growing online market selling it as a “research peptide” carries real dangers.
A University of Florida study of health records found people with memory problems who took glucosamine were more likely to progress to dementia. It is an association, not proof — but mouse experiments point to a plausible mechanism.
CRISPR Therapeutics’ CTX310 switches off the ANGPTL3 gene in the liver. One-year follow-up in a small first-in-human trial shows LDL and triglycerides stayed down with no serious treatment-related side effects.
Efsitora alfa turns 365 basal insulin injections a year into 52. It is the second weekly insulin cleared in the US this year — and a sign that diabetes care is shifting toward fewer, longer-acting doses.
Two Mount Sinai studies show how APOE4 turns key blood-vessel support cells into scar-forming cells, and that blocking one signal restored vessels in aged mice. It is early science with a clear lead.
Both promise to spot signs of dozens of cancers from a single blood draw, and neither is FDA-approved yet. Here is how they differ on what they measure, how often they raise false alarms, what happens after a positive result, and cost.